A recent research report from Founder Securities highlights that the fusion of 'AI+' is propelling the medical industry into a transformative phase of growth. High-tech innovations like Brain-Computer Interfaces (BCI) and surgical robots are gaining momentum in their deployment and broadening their scope of application. Non-invasive BCI technology is experiencing rapid advancements in medical rehabilitation, emotion regulation, and other sectors, fueled by stringent domestic standards for safety and ethics, as well as the substantial demand stemming from a vast population of patients requiring rehabilitation services. This presents a promising market outlook. Additionally, invasive BCI has achieved significant breakthroughs, with the anticipation of the first successful clinical case by 2025. Domestic companies are intensifying their self-research efforts and fostering collaborations to capitalize on these emerging market opportunities.